InterCure Ltd. (INCR)

InterCure Ltd. is a leading Israeli company focused on the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates both domestically and internationally, offering dried cannabis inflorescences and cannabis extract mixed with oil.

44/100 AI Score MCap 57M Vol 233K

Company Overview

CEOAlexander Rabinovich
Employees320
HeadquartersHerzliya, IL
IPO Year2019

InterCure Ltd. pioneers medical cannabis in Israel and globally, leveraging its integrated platform for research, cultivation, and distribution. With a focus on high-quality products and strategic biomed investments, InterCure is positioned to capitalize on the expanding medical cannabis market, despite current profitability challenges.

Investment Thesis

InterCure presents a compelling investment opportunity within the burgeoning medical cannabis market, particularly in Israel and expanding internationally. Despite a current negative P/E ratio of -2.25 and a concerning profit margin of -29.2%, the company's strategic positioning and integrated operations offer significant upside potential. Growth catalysts include increasing acceptance and legalization of medical cannabis globally, coupled with InterCure's focus on high-quality product development and strategic biomed investments. Key value drivers include expanding market share in existing and new geographies, optimizing production efficiency, and leveraging its established distribution network. The company's low beta of 0.32 suggests lower volatility compared to the broader market, making it an attractive option for risk-averse investors seeking exposure to the cannabis sector. Successful execution of its growth strategies and improved profitability could drive significant shareholder value in the medium to long term.

Key Highlights

  • Market capitalization of $0.05 billion reflects its current valuation in the market.
  • Negative P/E ratio of -2.25 indicates current unprofitability, requiring focus on operational efficiency.
  • Gross margin of 16.7% demonstrates potential for improvement through cost optimization and pricing strategies.
  • Low beta of 0.32 suggests lower volatility compared to the broader market, appealing to risk-averse investors.
  • No dividend yield reflects the company's focus on reinvesting earnings for growth.

Competitors

Strengths

  • Integrated platform from research to distribution.
  • Established presence in the Israeli medical cannabis market.
  • Focus on high-quality products.
  • Strategic investments in the biomed sector.

Weaknesses

  • Negative profit margin.
  • Limited international market presence.
  • Reliance on regulatory approvals.
  • Relatively small market capitalization.

Catalysts

  • Upcoming: Expansion into new international markets, driving revenue growth.
  • Ongoing: Development and launch of innovative cannabis-based products.
  • Ongoing: Strategic acquisitions and partnerships to expand market reach.
  • Ongoing: Increasing acceptance and legalization of medical cannabis globally.

Risks

  • Potential: Evolving regulations and legal frameworks impacting operations.
  • Ongoing: Intense competition from other cannabis producers.
  • Potential: Fluctuations in cannabis prices affecting profitability.
  • Potential: Changes in consumer preferences impacting demand.
  • Ongoing: Dependence on regulatory approvals for new products and market entry.

Growth Opportunities

  • Expansion into New International Markets: InterCure can capitalize on the increasing legalization of medical cannabis in various countries by expanding its distribution network and establishing partnerships with local players. The global medical cannabis market is projected to reach billions of dollars in the coming years, offering significant revenue potential for InterCure. Timeline: Ongoing, with a focus on strategic market entry over the next 3-5 years.
  • Development of Innovative Cannabis-Based Products: Investing in research and development to create new and innovative cannabis-based products, such as targeted therapies for specific medical conditions, can drive revenue growth and enhance InterCure's competitive advantage. The market for specialized cannabis products is growing rapidly, driven by increasing patient demand. Timeline: Ongoing, with new product launches expected within the next 1-2 years.
  • Strategic Acquisitions and Partnerships: Acquiring or partnering with complementary businesses, such as cannabis cultivation facilities or distribution companies, can expand InterCure's market reach and strengthen its supply chain. Strategic alliances can also provide access to new technologies and expertise. Timeline: Ongoing, with potential acquisitions and partnerships in the next 1-3 years.
  • Increased Focus on Branding and Marketing: Strengthening its brand image and marketing efforts can enhance InterCure's visibility and attract new customers. Investing in digital marketing, social media campaigns, and patient education programs can drive brand awareness and loyalty. Timeline: Ongoing, with continuous improvement in marketing strategies.
  • Optimization of Production and Distribution Processes: Improving the efficiency of its cultivation, production, and distribution processes can reduce costs and increase profitability. Implementing advanced technologies and streamlining operations can enhance InterCure's competitiveness. Timeline: Ongoing, with continuous process improvements.

Opportunities

  • Expansion into new international markets.
  • Development of innovative cannabis-based products.
  • Strategic acquisitions and partnerships.
  • Increasing acceptance and legalization of medical cannabis.

Threats

  • Evolving regulations and legal frameworks.
  • Intense competition from other cannabis producers.
  • Fluctuations in cannabis prices.
  • Potential changes in consumer preferences.

Competitive Advantages

  • Integrated platform encompassing research, cultivation, production, and distribution.
  • Established brand recognition in the Israeli medical cannabis market.
  • Strategic investments in the biomed sector.
  • Stringent quality control standards ensuring product safety and efficacy.

About

InterCure Ltd. was established in 1994 and has evolved into a prominent player in the medical cannabis industry. Headquartered in Herzliya, Israel, the company operates an integrated platform encompassing research, cultivation, production, marketing, and distribution of medical cannabis products. InterCure's core offerings include dried cannabis inflorescences and cannabis extract mixed with oil, catering to the growing demand for medical cannabis treatments. The company has expanded its reach beyond Israel, targeting international markets to capitalize on the global legalization and acceptance of medical cannabis. InterCure also strategically invests in the biomed sector, diversifying its portfolio and exploring synergies between medical cannabis and other biomedical advancements. Despite a challenging financial landscape reflected in its negative profit margin, InterCure continues to focus on expanding its market share and enhancing its product offerings. The company's commitment to research and development aims to drive innovation and solidify its position as a leader in the medical cannabis space. InterCure's cultivation and production processes adhere to stringent quality standards, ensuring the safety and efficacy of its products. The company's distribution network spans across Israel and select international markets, facilitating access to medical cannabis for patients in need. InterCure's strategic investments in the biomed sector reflect its long-term vision of integrating medical cannabis with broader healthcare solutions.

What They Do

  • Researches and develops medical cannabis products.
  • Cultivates cannabis plants in controlled environments.
  • Produces dried cannabis inflorescences and cannabis extract mixed with oil.
  • Markets medical cannabis products to patients and healthcare providers.
  • Distributes medical cannabis products through its network in Israel and internationally.
  • Invests in the biomed sector to explore synergies with medical cannabis.

Business Model

  • Cultivates and produces medical cannabis products.
  • Sells products directly to patients and through distributors.
  • Generates revenue through product sales and licensing agreements.

Industry Context

InterCure operates within the rapidly evolving medical cannabis industry, characterized by increasing legalization and acceptance globally. The market is driven by growing awareness of the therapeutic benefits of cannabis and a shift towards alternative medical treatments. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers. InterCure differentiates itself through its integrated platform, focusing on high-quality production and strategic investments in the biomed sector. The industry is subject to evolving regulations and varying legal frameworks across different jurisdictions, creating both opportunities and challenges for companies like InterCure. The global medical cannabis market is projected to experience significant growth in the coming years, presenting substantial opportunities for companies with established infrastructure and strong brand recognition.

Key Customers

  • Patients seeking medical cannabis treatments.
  • Healthcare providers prescribing medical cannabis.
  • Distributors and retailers selling medical cannabis products.
AI Confidence: 71% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 2023 $27M $1M $0.00
Q1 2023 $29M $58,440 $0.00
Q4 2022 $29M $2M $0.00
Q3 2022 $30M $2M $0.00

Source: Company filings

Chart & Info

Price Chart

InterCure Ltd. (INCR) stock price: $1.04 (+0.01, +0.97%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
  • •Community sentiment has turned more positive as discussions around cannabis regulation and market expansion gain traction.
  • •Analysts have noted increasing interest in the cannabis sector, with InterCure positioned well due to its established market presence.
  • •The company's recent product launches have generated buzz, highlighting innovation and a commitment to capturing new market segments.

Why Bear

  • •Concerns over regulatory hurdles persist, with potential changes in legislation that could impact operations and market access.
  • •Social media sentiment has shown fluctuations, indicating uncertainty among retail investors regarding the company's direction.
  • •Increased competition in the cannabis market may pressure InterCure's market share, raising concerns about long-term sustainability.
  • •Recent earnings reports have not met market expectations, leading to skepticism about the company's growth trajectory moving forward.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
232,425

Rationale

AI-generated technical analysis for INCR including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss InterCure Ltd. (INCR) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for INCR.

Make a Prediction

Set your price target for InterCure Ltd. (INCR), choose a timeframe, and track your prediction accuracy.

Current price: $1.04

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INCR.

Price Targets

Wall Street price target analysis for INCR.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

43.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 3/100

    Gross margin of 16.7% is below average, suggesting thin margins and potential pricing pressure.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates INCR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does InterCure Ltd. do?

InterCure Ltd. is an Israeli-based company involved in the medical cannabis industry. The company operates an integrated platform encompassing the research, cultivation, production, marketing, and distribution of medical cannabis products. InterCure offers dried cannabis inflorescences and cannabis extract mixed with oil, catering to the growing demand for medical cannabis treatments. The company focuses on expanding its market share and enhancing its product offerings, with a commitment to research and development to drive innovation and solidify its position as a leader in the medical cannabis space. InterCure also strategically invests in the biomed sector, reflecting its long-term vision of integrating medical cannabis with broader healthcare solutions.

Is INCR stock a good buy?

INCR stock presents a mixed investment profile. While the company operates in a high-growth industry and has an integrated platform, its negative P/E ratio of -2.25 and a profit margin of -29.2% raise concerns about current profitability. The low beta of 0.32 suggests lower volatility. Potential investors should carefully consider the company's growth opportunities, such as international expansion and new product development, against the risks associated with evolving regulations and intense competition. A turnaround in profitability and successful execution of growth strategies are crucial for INCR to deliver shareholder value.

What are the main risks for INCR?

InterCure faces several key risks. Evolving regulations and legal frameworks in the medical cannabis industry can significantly impact its operations and market access. Intense competition from other cannabis producers could erode market share and pricing power. Fluctuations in cannabis prices can affect profitability. Changes in consumer preferences and demand for medical cannabis products could impact revenue. The company's dependence on regulatory approvals for new products and market entry poses a risk to its growth plans. Investors should carefully monitor these risks and their potential impact on InterCure's financial performance.

Is INCR a good stock to buy?

Whether INCR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the INCR MoonshotScore?

The MoonshotScore for INCR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is INCR data updated?

INCR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to INCR is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for INCR?

Growth catalysts for InterCure Ltd. (INCR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes InterCure Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are INCR's main competitors?

InterCure Ltd. (INCR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether INCR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about INCR?

Wall Street analyst coverage for INCR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is INCR's market cap?

Market capitalization (market cap) for INCR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows INCR's current market cap alongside enterprise value and other valuation metrics.

How has INCR stock performed recently?

INCR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing INCR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in INCR?

Key risk categories for INCR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures INCR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling INCR?

Insider trading activity for INCR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is INCR a good stock for beginners?

InterCure Ltd. (INCR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is INCR for first-time investors?

Every stock carries risk, including InterCure Ltd. (INCR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like INCR.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on the most recent available information. The medical cannabis industry is subject to rapid changes in regulations and market conditions.
Data Sources
profilefundamentalsexistingCopy